Vemurafenib, a drug originally approved for use in patients with BRAF-positive melanoma, has also shown promising anti-tumor activity in some patients harboring this same mutation in thyroid cancer, according to the results of a study published in Lancet Oncology.
At the 2016 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, researchers presented the results of a genetic blood test called NETest®, which measures the specific NET genes circulating in the blood that are believed to predict responsiveness to peptide receptor radionuclide therapy
Using biomarkers to guide treatment in clinical trials may yield higher response rates than similar drugs not guided by biomarkers, according to an abstract presented at the American Society of Clinical Oncology Annual Meeting (June 3-7, 2016; Chicago, IL).
For a personalized cancer therapy program at Mount Sinai, researchers generated data on the genetic makeup of both patients and their tumors in order to determine whether this in-depth characterization would lead to improved results.
Incidence of a common adverse event should not be considered a hindrance to the administration of everolimus for patients with cancer, according to a recent study.
A team of researchers have developed a novel tool for calculating and displaying the survival statistics of patients with cancer depending on their genetic profile that could help practitioners better track mutation-specific outcomes.